• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.

作者信息

Shaughnessy Ciaran A, Zeitlin Pamela L, Bratcher Preston E

机构信息

Department of Pediatrics, National Jewish Health, Denver, CO, USA.

Department of Pediatrics, University of Colorado Anschutz Medical Center, Aurora, CO, USA.

出版信息

Sci Rep. 2021 Oct 25;11(1):21295. doi: 10.1038/s41598-021-00539-5.

DOI:10.1038/s41598-021-00539-5
PMID:34697341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8546072/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf7/8546072/fe90e7e14b28/41598_2021_539_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf7/8546072/9bf0d3c4c88a/41598_2021_539_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf7/8546072/fe90e7e14b28/41598_2021_539_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf7/8546072/9bf0d3c4c88a/41598_2021_539_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4cf7/8546072/fe90e7e14b28/41598_2021_539_Fig4_HTML.jpg

相似文献

1
Author Correction: Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment.作者更正：依列卡福托是一种囊性纤维化跨膜传导调节因子（CFTR）增强剂，在急性和慢性治疗期间与依伐卡托协同作用。
Sci Rep. 2021 Oct 25;11(1):21295. doi: 10.1038/s41598-021-00539-5.
2
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.在纯合子 F508del 突变的囊性纤维化患者中，elexacaftor 加 tezacaftor 加 ivacaftor 联合治疗方案的疗效和安全性：一项双盲、随机、3 期临床试验。
Lancet. 2019 Nov 23;394(10212):1940-1948. doi: 10.1016/S0140-6736(19)32597-8. Epub 2019 Oct 31.
3
Elexacaftor/Ivacaftor/Tezacaftor: First Approval.依伐卡托/埃乐卡福特/泰泽卡福特：首次批准。
Drugs. 2019 Dec;79(18):2001-2007. doi: 10.1007/s40265-019-01233-7.
4
Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy.依列卡福妥-替扎卡福妥-依伐卡托：首个三联组合型囊性纤维化跨膜传导调节因子调控疗法
J Pediatr Pharmacol Ther. 2020;25(3):192-197. doi: 10.5863/1551-6776-25.3.192.
5
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.三药复方（Trikafta）依利卓艾他康唑/艾美拉唑/卡博替尼（elexacaftor-tezacaftor-ivacaftor）对 F508del 及罕见 CFTR 突变体的别构折叠校正。
JCI Insight. 2020 Sep 17;5(18):139983. doi: 10.1172/jci.insight.139983.
6
The preclinical discovery and development of the combination of ivacaftor + tezacaftor used to treat cystic fibrosis.用于治疗囊性纤维化的依伐卡托+替扎卡托组合的临床前发现与开发。
Expert Opin Drug Discov. 2020 Aug;15(8):873-891. doi: 10.1080/17460441.2020.1750592. Epub 2020 Apr 15.
7
The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.囊性纤维化跨膜传导调节因子增效剂依伐卡托增强黏液纤毛清除功能，消除香烟烟雾对囊性纤维化跨膜传导调节因子的抑制作用。
Am J Respir Cell Mol Biol. 2017 Jan;56(1):99-108. doi: 10.1165/rcmb.2016-0226OC.
8
Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.在患有囊性纤维化和晚期肺部疾病的患者中开始使用 Elexacaftor-Tezacaftor-Ivacaftor 后的快速改善。
Am J Respir Crit Care Med. 2021 Jul 1;204(1):64-73. doi: 10.1164/rccm.202011-4153OC.
9
Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.白藜芦醇和 ivacaftor 可增强 G551D CFTR 通道：对囊性纤维化鼻窦病的治疗意义。
Int Forum Allergy Rhinol. 2019 Jan;9(1):100-105. doi: 10.1002/alr.22202. Epub 2018 Aug 27.
10
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of Pharmacology and Clinical Translation.新型囊性纤维化跨膜传导调节因子调节剂作为囊性纤维化的新药：药理学与临床转化概述
ACS Pharmacol Transl Sci. 2019 Oct 2;3(1):4-10. doi: 10.1021/acsptsci.9b00060. eCollection 2020 Feb 14.

引用本文的文献

1
Structure-based discovery of CFTR potentiators and inhibitors.基于结构的 CFTR 增强剂和抑制剂的发现。
Cell. 2024 Jul 11;187(14):3712-3725.e34. doi: 10.1016/j.cell.2024.04.046. Epub 2024 May 28.